Recently Featured

BioAegis and Prenosis partner for inflammatory disease therapies

May 5, 2026
BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases. This collaboration aims to leverage Prenosis’ AI platform to enhance the development of therapies that target specific inflammatory pathways, potentially improving treatment outcomes for patients suffering from these conditions. The integration of artificial intelligence in drug development signifies…

Novartis launches ‘Sjöut for Sjögren’s’ campaign, teams with Carrie Ann Inaba

May 4, 2026
Novartis has initiated a new disease awareness campaign focused on Sjögren’s syndrome, enlisting the support of prominent dancer and TV personality Carrie Ann Inaba. This strategic partnership aims to elevate the visibility of Sjögren’s syndrome, a chronic autoimmune condition that often goes undiagnosed, impacting millions worldwide. The campaign, titled ‘Sjöut for Sjögren’s,’ seeks to educate…

Public Notification: Slimina contains hidden drug ingredient

May 4, 2026
The Food and Drug Administration (FDA) has issued a public notification advising against the purchase or use of Slimina, a weight loss product being marketed on various online platforms, including www.effectivehealthyproducts.com, and potentially in some retail outlets. This warning comes after the FDA discovered that Slimina contains an undisclosed drug ingredient, raising significant safety concerns…

Ongoing Cases